Arno Therapeutics (ARNI) 0.5800 $ARNI
Arno Therapeutics Announces Issuance of First Onapristone Patent
GlobeNewswire - Thu Jun 04, 7:30AM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of therapeutics for cancer and other life threatening diseases, today announced that United States Patent Number 9,046,534 has been issued by the U.S. Patent and Trademark Office (USPTO) related to the methods and systems for identifying and treating patients with anti-progestin sensitive tumors using the Company's lead product candidate, onapristone. The patent, which Arno has exclusively licensed from Invivis Pharmaceuticals, Inc., establishes that the focal nuclear distribution pattern of the progesterone receptor can be used to identify tumors susceptible to treatment with anti-progestin therapy.
Arno Therapeutics Announces Cooperative Research and Development Agreement With US Army Medical Research Institute of Infectious Diseases to Test Antiviral Activity of AR-12
GlobeNewswire - Wed Jun 03, 7:30AM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of therapeutics for the treatment of cancer and other life threatening diseases, today announced it has entered into a Cooperative Research and Development Agreement (CRADA) Material Transfer Agreement with the US Army Medical Research Institute of Infectious Diseases (USAMRIID) to evaluate the anti-viral activity of AR-12 and various analogues against Ebola and other viruses of biodefense interest.
Arno Therapeutics Announces AR-12 Antiviral Data Against Multiple Hemorrhagic Fevers Published Online in Antiviral Research
GlobeNewswire - Thu May 28, 10:15AM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on developing therapeutics in cancer and other life threatening diseases, today announced that in-vitro data for its investigational agent AR-12 (also referred to as OSU-03012) generated by the Viral Special Pathogens Branch of the U.S. Centers for Disease Control and Prevention (CDC) was published online in the journal Antiviral Research.
Arno Therapeutics Reports First Quarter 2015 Financial and Business Update
GlobeNewswire - Fri May 15, 3:35PM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of therapeutics for cancer and other life threatening diseases, today announced financial results for the quarter ended March 31, 2015 and provided an update on recent clinical developments for its lead compound, onapristone.
Arno Therapeutics Announces Preclinical Data Demonstrating Broad-Spectrum Antiviral Activity for AR-12
GlobeNewswire - Thu May 14, 3:15PM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of therapeutics for the treatment of cancer and other life threatening diseases, today announced data supporting the development of AR-12 as a broad-spectrum, host-directed antiviral drug. Results of the preclinical studies were presented today at the 28 Annual International Conference on Antiviral Research (ICAR), hosted by the International Society for Antiviral Research (ISAR) and being held May 11 - 15, 2015 in Rome, Italy.
Arno Therapeutics Announces Data Validating Continued Onapristone and Companion Diagnostic Development at ASCO Annual Meeting 2015
GlobeNewswire - Wed May 13, 4:30PM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of therapeutics for cancer and other life threatening diseases, today announced promising data supporting the ongoing clinical development program for lead compound onapristone to be presented at the upcoming 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, being held May 29-June 2 in Chicago, IL.
Arno Therapeutics Receives USPTO Notice of Allowance for Two Important Patents Covering Lead Compound Onapristone
GlobeNewswire - Thu May 07, 7:30AM CDT
Patents to Cover Methods of Use and Diagnostic Methods for Identifying Anti-Progestin Sensitive Tumors
Small Cap Biotechs Under $1 Billion Market Cap To Watch Into ASCO 2015
Daniel Ward - at Seeking Alpha - Mon May 04, 7:31AM CDT
LOXO: 16.35 (-0.07), OGXI: 2.23 (+0.13), XBI: 252.57 (+5.62), IBB: 372.80 (+6.06)
Arno Therapeutics Receives European Orphan Drug Designation for AR-12 to Treat Two Infectious Diseases
GlobeNewswire - Thu Apr 30, 7:30AM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of therapeutics for the treatment of cancer and other life threatening diseases, today announced that the European Commission, acting on the recommendation from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA), has designated AR-12 as an orphan medicinal product for the treatment of two separate infectious diseases, cryptococcosis and tularaemia.
Arno Therapeutics to Present Three Posters Supporting Onapristone Development at ASCO Annual Meeting 2015
GlobeNewswire - Wed Apr 29, 7:30AM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of therapeutics for cancer and other life threatening diseases, today announced that three posters supporting the ongoing clinical development program for lead compound onapristone will be presented at the upcoming 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, being held May 29-June 2 in Chicago, IL.
Arno Therapeutics to Present Promising Data From Phase I Trial of Onapristone at AACR Annual Meeting 2015
GlobeNewswire - Tue Apr 21, 7:30AM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of therapeutics for cancer and other life threatening diseases, today announced data from three posters supporting the ongoing clinical development program for lead compound onapristone at the American Association for Cancer Research (AACR) Annual Meeting 2015, being held April 18-22 in Philadelphia, Pa.
Arno Therapeutics Announces Three Poster Presentations at Upcoming AACR Annual Meeting 2015
GlobeNewswire - Mon Apr 13, 8:08AM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of therapeutics for cancer and other life threatening diseases, today announced the upcoming presentation of three posters supporting the ongoing clinical development program for lead compound onapristone at the American Association for Cancer Research (AACR) Annual Meeting 2015, being held April 18-22 in Philadelphia, PA.
Arno Therapeutics Reports Fourth Quarter 2014 Financial and Business Update
GlobeNewswire - Tue Mar 31, 3:38PM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development therapeutics for cancer and other life threatening diseases, today announced financial results for the quarter and year ended December 31, 2014 and provided an update on recent clinical developments for its lead compound, onapristone.
New Data Supporting Arno Therapeutics' HDAC Inhibitor AR-42 Published in The Journal of Urology
GlobeNewswire - Tue Mar 24, 7:30AM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of oncology therapeutics, today announced that data from a preclinical study demonstrate its histone-deacetylase (HDAC) inhibitor AR-42 in combination with cisplatin has a synergistic anti-tumor effect in bladder cancer models. These data were recently published online ahead of print in The Journal of Urology.
Arno Therapeutics to Present at 11th Annual Noble Equity Conference
GlobeNewswire - Thu Jan 08, 7:50AM CST
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of oncology therapeutics, today announced that Chief Operating Officer, Lawrence Kenyon, is scheduled to present at the Noble Financial Capital Markets' 11 Annual Equity Conference, being held January 18-21, 2015 at Club Med in Sandpiper Bay, FL.
Arno Therapeutics Doses First Patient in Expansion Stage of Modified Phase I/II Trial Evaluating Onapristone in Progesterone Receptor Positive Tumors
GlobeNewswire - Wed Dec 10, 8:00AM CST
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of oncology therapeutics, today announced that it has dosed the first patient in the Phase II component of a modified Phase I/II clinical study evaluating its lead compound onapristone in women with progesterone receptor expressing tumors. The Phase II study will include up to 29 patients with recurrent or metastatic endometrioid tumors that have been shown to express the activated progesterone receptor (APR), and who have received no more than one prior chemotherapy and no prior hormone therapy.
Arno Therapeutics to Present Data Further Validating Diagnostic Development of CDx for Onapristone at San Antonio Breast Cancer Symposium 2014
GlobeNewswire - Tue Dec 09, 8:11AM CST
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused primarily on the development of oncology therapeutics, today announced that data from a study supporting diagnostic development for its lead compound onapristone will be presented at a poster session at the 2014 San Antonio Breast Cancer Symposium (SABCS), being held December 9-13, 2014 in San Antonio, Texas. The symposium is hosted by The Cancer Therapy & Research Center (CTRC) at The University of Texas Health Sciences Center at San Antonio, the American Association for Cancer Research (AACR) and Baylor College of Medicine.
Arno Therapeutics announces changes in board
M2 - Fri Dec 05, 4:26AM CST
Biopharmaceutical company Arno Therapeutics (Other OTC:ARNI) reported on Thursday that it has named Dr Alexander Zukiwski, MD as a member of its board of directors and chief executive officer.
Arno Therapeutics Appoints Alexander Zukiwski, M.D. to Board of Directors
GlobeNewswire - Thu Dec 04, 7:30AM CST
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused primarily on the development of oncology therapeutics, today announced that it has appointed Alexander Zukiwski, M.D. to its Board of Directors. The Board of Directors also appointed Dr. Zukiwski as the Company's Chief Executive Officer. Dr. Zukiwski, who had served as the Company's Interim CEO since July 2014, will also continue in his role as Arno's Chief Medical Officer.
Arno Therapeutics Announces Issuance of First Onapristone Patent
GlobeNewswire - Thu Jun 04, 7:30AM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of therapeutics for cancer and other life threatening diseases, today announced that United States Patent Number 9,046,534 has been issued by the U.S. Patent and Trademark Office (USPTO) related to the methods and systems for identifying and treating patients with anti-progestin sensitive tumors using the Company's lead product candidate, onapristone. The patent, which Arno has exclusively licensed from Invivis Pharmaceuticals, Inc., establishes that the focal nuclear distribution pattern of the progesterone receptor can be used to identify tumors susceptible to treatment with anti-progestin therapy.
Arno Therapeutics Announces Cooperative Research and Development Agreement With US Army Medical Research Institute of Infectious Diseases to Test Antiviral Activity of AR-12
GlobeNewswire - Wed Jun 03, 7:30AM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of therapeutics for the treatment of cancer and other life threatening diseases, today announced it has entered into a Cooperative Research and Development Agreement (CRADA) Material Transfer Agreement with the US Army Medical Research Institute of Infectious Diseases (USAMRIID) to evaluate the anti-viral activity of AR-12 and various analogues against Ebola and other viruses of biodefense interest.
Arno Therapeutics Announces AR-12 Antiviral Data Against Multiple Hemorrhagic Fevers Published Online in Antiviral Research
GlobeNewswire - Thu May 28, 10:15AM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on developing therapeutics in cancer and other life threatening diseases, today announced that in-vitro data for its investigational agent AR-12 (also referred to as OSU-03012) generated by the Viral Special Pathogens Branch of the U.S. Centers for Disease Control and Prevention (CDC) was published online in the journal Antiviral Research.
Arno Therapeutics Reports First Quarter 2015 Financial and Business Update
GlobeNewswire - Fri May 15, 3:35PM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of therapeutics for cancer and other life threatening diseases, today announced financial results for the quarter ended March 31, 2015 and provided an update on recent clinical developments for its lead compound, onapristone.
Arno Therapeutics Announces Preclinical Data Demonstrating Broad-Spectrum Antiviral Activity for AR-12
GlobeNewswire - Thu May 14, 3:15PM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of therapeutics for the treatment of cancer and other life threatening diseases, today announced data supporting the development of AR-12 as a broad-spectrum, host-directed antiviral drug. Results of the preclinical studies were presented today at the 28 Annual International Conference on Antiviral Research (ICAR), hosted by the International Society for Antiviral Research (ISAR) and being held May 11 - 15, 2015 in Rome, Italy.
Arno Therapeutics Announces Data Validating Continued Onapristone and Companion Diagnostic Development at ASCO Annual Meeting 2015
GlobeNewswire - Wed May 13, 4:30PM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of therapeutics for cancer and other life threatening diseases, today announced promising data supporting the ongoing clinical development program for lead compound onapristone to be presented at the upcoming 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, being held May 29-June 2 in Chicago, IL.
Arno Therapeutics Receives USPTO Notice of Allowance for Two Important Patents Covering Lead Compound Onapristone
GlobeNewswire - Thu May 07, 7:30AM CDT
Patents to Cover Methods of Use and Diagnostic Methods for Identifying Anti-Progestin Sensitive Tumors
Small Cap Biotechs Under $1 Billion Market Cap To Watch Into ASCO 2015
Daniel Ward - at Seeking Alpha - Mon May 04, 7:31AM CDT
LOXO: 16.35 (-0.07), OGXI: 2.23 (+0.13), XBI: 252.57 (+5.62), IBB: 372.80 (+6.06)
Arno Therapeutics Receives European Orphan Drug Designation for AR-12 to Treat Two Infectious Diseases
GlobeNewswire - Thu Apr 30, 7:30AM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of therapeutics for the treatment of cancer and other life threatening diseases, today announced that the European Commission, acting on the recommendation from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA), has designated AR-12 as an orphan medicinal product for the treatment of two separate infectious diseases, cryptococcosis and tularaemia.
Arno Therapeutics to Present Three Posters Supporting Onapristone Development at ASCO Annual Meeting 2015
GlobeNewswire - Wed Apr 29, 7:30AM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of therapeutics for cancer and other life threatening diseases, today announced that three posters supporting the ongoing clinical development program for lead compound onapristone will be presented at the upcoming 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, being held May 29-June 2 in Chicago, IL.
Arno Therapeutics to Present Promising Data From Phase I Trial of Onapristone at AACR Annual Meeting 2015
GlobeNewswire - Tue Apr 21, 7:30AM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of therapeutics for cancer and other life threatening diseases, today announced data from three posters supporting the ongoing clinical development program for lead compound onapristone at the American Association for Cancer Research (AACR) Annual Meeting 2015, being held April 18-22 in Philadelphia, Pa.
Arno Therapeutics Announces Three Poster Presentations at Upcoming AACR Annual Meeting 2015
GlobeNewswire - Mon Apr 13, 8:08AM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of therapeutics for cancer and other life threatening diseases, today announced the upcoming presentation of three posters supporting the ongoing clinical development program for lead compound onapristone at the American Association for Cancer Research (AACR) Annual Meeting 2015, being held April 18-22 in Philadelphia, PA.
Arno Therapeutics Reports Fourth Quarter 2014 Financial and Business Update
GlobeNewswire - Tue Mar 31, 3:38PM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development therapeutics for cancer and other life threatening diseases, today announced financial results for the quarter and year ended December 31, 2014 and provided an update on recent clinical developments for its lead compound, onapristone.
New Data Supporting Arno Therapeutics' HDAC Inhibitor AR-42 Published in The Journal of Urology
GlobeNewswire - Tue Mar 24, 7:30AM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of oncology therapeutics, today announced that data from a preclinical study demonstrate its histone-deacetylase (HDAC) inhibitor AR-42 in combination with cisplatin has a synergistic anti-tumor effect in bladder cancer models. These data were recently published online ahead of print in The Journal of Urology.
Arno Therapeutics to Present at 11th Annual Noble Equity Conference
GlobeNewswire - Thu Jan 08, 7:50AM CST
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of oncology therapeutics, today announced that Chief Operating Officer, Lawrence Kenyon, is scheduled to present at the Noble Financial Capital Markets' 11 Annual Equity Conference, being held January 18-21, 2015 at Club Med in Sandpiper Bay, FL.
Arno Therapeutics Doses First Patient in Expansion Stage of Modified Phase I/II Trial Evaluating Onapristone in Progesterone Receptor Positive Tumors
GlobeNewswire - Wed Dec 10, 8:00AM CST
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of oncology therapeutics, today announced that it has dosed the first patient in the Phase II component of a modified Phase I/II clinical study evaluating its lead compound onapristone in women with progesterone receptor expressing tumors. The Phase II study will include up to 29 patients with recurrent or metastatic endometrioid tumors that have been shown to express the activated progesterone receptor (APR), and who have received no more than one prior chemotherapy and no prior hormone therapy.
Arno Therapeutics to Present Data Further Validating Diagnostic Development of CDx for Onapristone at San Antonio Breast Cancer Symposium 2014
GlobeNewswire - Tue Dec 09, 8:11AM CST
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused primarily on the development of oncology therapeutics, today announced that data from a study supporting diagnostic development for its lead compound onapristone will be presented at a poster session at the 2014 San Antonio Breast Cancer Symposium (SABCS), being held December 9-13, 2014 in San Antonio, Texas. The symposium is hosted by The Cancer Therapy & Research Center (CTRC) at The University of Texas Health Sciences Center at San Antonio, the American Association for Cancer Research (AACR) and Baylor College of Medicine.
Arno Therapeutics announces changes in board
M2 - Fri Dec 05, 4:26AM CST
Biopharmaceutical company Arno Therapeutics (Other OTC:ARNI) reported on Thursday that it has named Dr Alexander Zukiwski, MD as a member of its board of directors and chief executive officer.
Arno Therapeutics Appoints Alexander Zukiwski, M.D. to Board of Directors
GlobeNewswire - Thu Dec 04, 7:30AM CST
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused primarily on the development of oncology therapeutics, today announced that it has appointed Alexander Zukiwski, M.D. to its Board of Directors. The Board of Directors also appointed Dr. Zukiwski as the Company's Chief Executive Officer. Dr. Zukiwski, who had served as the Company's Interim CEO since July 2014, will also continue in his role as Arno's Chief Medical Officer.
